Visualizando por Autor André Poisl Fay

Ir a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
o entre con las primeras letras:  
Mostrando reg. 1 a 9 de 9
Fecha de PublicaciónTítuloAutor(s)
2015Cost of preventing an event (COPE) of enzalutamide versus abiraterone plus prednisone in men with metastatic castration-resistant prostate cancer under the Brazilian private health care system perspectiveStephen Doral Stefani; Vanessa Teich; André Poisl Fay, etc.
2017Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trialsMOREIRA, RAPHAEL B.; Marcio Debiasi; FRANCINI, EDOARDO, etc.
2015HER2 as a target in invasive urothelial carcinomaBELLMUNT, JOAQUIM; WERNER, LILLIAN; BAMIAS, ARISTOTLE, etc.
2016Número necessário a tratar (NNT) e custo por evento evitado (COPE) de enzalutamida e acetato de abiraterona para o tratamento de câncer de próstata resistente à castração que falharam a terapia de privação de androgênioSTEFANI, STEPHEN; SASSE, ANDRÉ; André Poisl Fay, etc.
2016Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaDE VELASCO, GUILLERMO; GRAY, KATHRYN P.; HAMIEH, LANA, etc.
2015Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré Poisl Fay; SIGNORETTI, SABINA; CALLEA, MARCELLA, etc.
2016Quality of life of cancer patients on the wave of immunotherapyRAMOS, FERNANDA B. PRUSKI; André Poisl Fay
2015Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial TumorsBELLMUNT, JOAQUIM; WERNER, LILLIAN; LEOW, JEFFREY J., etc.
2016The Management of Immune-related Adverse Events Associated with Immune Checkpoint BlockadeAndré Poisl Fay; Raphael Brandao Moreira; Paulo R. S.Nunes Filho, etc.